<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Heart failure in the long-term care setting.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Medical Directors Association (AMDA). Heart  failure in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2010. 24 p.  [71 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: American Medical Directors Association (AMDA). Heart failure. Columbia (MD): American Medical Directors Association (AMDA); 2002. 18 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Congestive heart failure, unspecified  (428.0); Diagnostic ultrasound of heart  (88.72); Electrocardiogram  (89.52); Heart failure, unspecified  (428.9)"/><FieldValue Value="MSH: Adrenergic beta-Agonists ; Angiotensin-Converting Enzyme Inhibitors ; Blood Cell Count ; Body Weight ; Calcium Channel Blockers ; Coronary Angiography ; Counseling ; Diet Therapy ; Digoxin ; Diuretics ; Echocardiography ; Electrocardiography ; Heart Failure ; Hydralazine ; Influenza Vaccines ; Isosorbide Dinitrate ; Kidney Function Tests ; Liver Function Tests ; Long-Term Care ; Medical History Taking ; Medication Therapy Management ; Natriuretic Peptide, Brain ; Nitrates ; Palliative Care ; Patient Care Planning ; Pneumococcal Vaccines ; Radionuclide Imaging ; Rehabilitation ; Risk Assessment ; Severity of Illness Index ; Spiritual Therapies ; Spironolactone ; Terminal Care ; Thyroid Function Tests ; Vital Signs "/><FieldValue Value="MTH: Adrenergic beta-Agonists ; Aldosterone Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; blood cell count ; Body Weight ; Brain natriuretic peptide measurement ; Calcium Channel Blockers ; Congestive heart failure ; Coronary angiography ; Counseling ; Diet education ; Diet therapy ; Digoxin ; Echocardiography ; Electrocardiography ; Electrolytes measurement, serum ; Heart failure ; Influenza virus vaccine ; Isosorbide Dinitrate ; Kidney Function Tests ; Left ventricular ejection fraction ; Liver Function Tests ; long-term care ; Magnesium measurement ; Nesiritide ; Nitrates ; Palliative Care ; Plain chest X-ray ; Pneumococcal vaccine ; Radionuclide Imaging ; Rehabilitation therapy ; Risk Assessment ; Spiritual Therapies ; Spironolactone ; terminal patient care ; Thyroid Function Tests ; Vital signs "/><FieldValue Value="PDQ: digoxin ; nesiritide ; radionuclide imaging ; spironolactone "/><FieldValue Value="SNOMEDCT_US: Aldosterone antagonist  (346312000); Aldosterone antagonist  (372603003); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Blood cell count  (88308000); Body weight  (27113001); Brain natriuretic peptide measurement  (390917008); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Congestive heart failure  (42343007); Coronary angiography  (33367005); Counseling  (129441002); Counseling  (409063005); Diet education  (11816003); Dietary management education, guidance, and counseling  (424753004); Digoxin  (387461009); Digoxin  (796001); Diuretic  (30492008); Diuretic  (372695000); Dying care  (182964004); Dying care  (385736008); Echocardiography  (40701008); Electrocardiographic procedure  (29303009); Electrolytes measurement, serum  (20109005); Emotional and psychosocial support and education  (395094003); Fasting lipid profile  (252150008); Heart failure  (84114007); Hydralazine  (22696000); Hydralazine  (387125005); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Isosorbide dinitrate  (387332007); Isosorbide dinitrate  (5924003); Left ventricular ejection fraction  (250908004); Liver function tests - general  (26958001); Liver function tests - general  (271552009); Magnesium measurement  (38151008); N terminal pro-brain natriuretic peptide level  (414799001); Nesiritide  (385678006); Nesiritide  (385679003); Nesiritide  (385680000); Nesiritide  (407059007); Nitrate salt  (89119000); Nuclear medicine imaging procedure  (373205008); Palliative care  (103735009); Plain chest X-ray  (399208008); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Rehabilitation therapy  (52052004); Renal function study  (44277000); Risk assessment  (225338004); Spiritual support  (385728004); Spiritual support  (385988005); Spiritual support  (386444001); Spiritual therapy  (105390002); Spironolactone  (13929005); Spironolactone  (387078006); Thyroid panel  (35650009); Vital signs  (46680005)"/><FieldValue Value="UMD: Physiologic Monitor Modules, Electrocardiography  (20-771); Radiographic Systems, Digital, Chest  (18-431); Scanning Systems, Ultrasonic, Cardiac  (17-422)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Heart failure&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Allied Health Personnel" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To improve the quality of care delivered to patients with heart failure in long-term care facilities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To guide the recognition, assessment, and management of patients with heart failure who reside in long-term care facilities &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Elderly residents of long-term care facilities&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Screening/Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Identification of patients with a history of heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment for signs, symptoms, and risk factors for heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation and classification of severity of heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initial workup (if determined appropriate) for reversible etiologies of heart failure (chest x-ray, coronary angiography, detailed cardiopulmonary history, electrocardiogram, laboratory tests [complete blood count, serum electrolytes, thyroid function, renal function, liver function, and lipid profile], physical examination, serum levels of brain natriuretic peptide [BNP] and N-terminal-proBNP [NT-proBNP]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Imaging&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Echocardiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Radionuclide scanning &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Determination of whether interventions are appropriate for reversible etiologies of heart failure &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Development of an individualized treatment plan and define treatment goals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Management of fluid volume overload: loop diuretics &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of reduced left ventricular ejection fraction (LVEF): angiotensin-converting enzyme (ACE) inhibitors, aldosterone antagonists, beta-blockers, digoxin, diuretics, isosorbide dinitrate/hydralazine &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of heart failure with preserved LVEF: ACE inhibitors, beta-blockers, calcium-channel blockers, diuretics, nitrates &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nonpharmacologic treatment as indicated&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Psychosocial and spiritual support &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dietary counseling &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Rehabilitation consultation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Vaccinations (pneumococcal and influenza) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Palliative care as appropriate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Counseling on end-of-life planning &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring of patient's condition and response to treatment (signs and symptoms, weight, vital signs, functional performance, electrolytes, renal function, magnesium, drug levels where indicated) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Survival &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptoms of heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise tolerance and functional capacity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of drug treatments &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospitalization rate &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Medline, PubMed, and geriatric-specific journals such as the Journal of the American Medical Directors Association (JAMDA), Annals of Long Term Care, and Journal of the American Geriatrics Society (JAGS) were searched from May 2009 through February 2011. Studies were included if they met the following criteria:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Studies that are valid, consistent, applicable and clinically relevant &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies where the recommendation is supported by fair evidence (based on studies that are valid, but there are some concerns about the volume, consistency, applicability and clinical relevance of the evidence that may cause some uncertainty but are not likely to be overturned by other evidence) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Searches were specific to the guideline topic under consideration.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /><FieldValue Value="Review of Published Meta-Analyses" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Original guidelines are developed by interdisciplinary workgroups, using a process that combines evidence and consensus-based approaches. Workgroups include practitioners and others involved in patient care in long-term care facilities. Beginning with a general guideline developed by an agency, association, or organization such as the Agency for Healthcare Research and Quality (AHRQ), pertinent articles and information, and a draft outline, each group works to make a concise, usable guideline that is tailored to the long-term care setting. Because scientific research in the long-term care population is limited, many recommendations are based on the expert opinion of practitioners in the field. A bibliography is provided for individuals who desire more detailed information.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Guideline revisions are completed under the direction of the Clinical Practice Guideline Steering Committee. The committee incorporates information published in peer-reviewed journals after the original guidelines appeared as well as comments and recommendations not only from experts in the field addressed by the guideline but also from &quot;hands-on&quot; long-term care practitioners and staff.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All American Medical Directors Association (AMDA) clinical practice guidelines undergo external review. The draft guideline is sent to approximately 175+ reviewers. These reviewers include American Medical Directors Association physician members and independent physicians, specialists, and organizations that are knowledgeable of the guideline topic and the long-term care setting. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;AMDA's guidelines are supported by the following associations/organizations, who are members of its Clinical Practice Guideline Steering Committee. These associations/organizations all have representatives who participate in the external review phase and officially sign off on the guideline before publication: American Association of Homes and Services for the Aging (Now LeadingAge); American College of Health Care Administrators; American Geriatrics Society; American Health Care Association; American Society of Consultant Pharmacists; Gerontological Advanced Practice Nurses Association; Direct Care Alliance; National Association of Directors of Nursing Administration in Long-Term Care; National Association of Health Care Assistants.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;&lt;strong&gt;Note from the American Medical Directors Association (AMDA) and the National Guideline Clearinghouse (NGC)&lt;/strong&gt;&lt;/em&gt;: The original full-text guideline provides an algorithm on &quot;Heart Failure in the Long Term Care Setting&quot; to be used in conjunction with the written text. Refer to the &quot;Guideline Availability&quot; field for information on obtaining the algorithm, as well as the full text of the guideline, which provides additional details.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Recognition&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 1&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Identify individuals with a history of heart failure&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Use the transfer summary and other referral data as well as the long-term care (LTC) facility clinical record to help to identify patients with heart failure. Copies of electrocardiograms, echocardiograms, cardiology consultation reports, and chest x-ray reports may be particularly useful when the patient is transferred from the hospital to the LTC facility.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 2&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Identify individuals who currently have heart failure&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Practitioners and nurses should evaluate the patient for signs and symptoms of heart failure and should document their findings. Refer to Tables 1 and 2 in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 3&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Evaluate the patient for the presence of risk factors for heart failure&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the patient does not have signs and symptoms but has a history of heart failure, summarize past and current assessment and treatment. Evaluate the patient's risk factors for heart failure (see Table 3 in the original guideline document) and document the findings in the patient's medical record. If no risk factors are found, continue to review the patient at least quarterly for the emergence of risk factors.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the patient has risk factors, determine the effect that addressing these risk factors would have on the goals of therapy.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Assessment&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The severity of heart failure can be classified symptomatically by the use of a scheme such as the New York Heart Association (NYHA) functional classification, which groups patients according to the amount of effort needed to produce heart failure symptoms (see Table 4 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 4&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Decide if a workup is appropriate&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A workup may not be indicated if the patient has a terminal or end-stage condition, if the workup would not change the management course, or if the patient would refuse treatment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 5&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Perform initial imaging studies&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Workup for Heart Failure&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Workup for Heart Failure&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Chest x-ray &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Coronary angiography (in selected patients who may benefit from coronary revascularization) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Detailed cardiopulmonary history &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Electrocardiogram &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Laboratory tests (complete blood count, serum electrolytes including calcium and magnesium, thyroid function, renal function, liver function, and lipid profile) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Serum levels of BNP and NT-proBNP can help in risk stratification and in situations in which the clinical diagnosis of HF is not certain* (not routinely included in the initial workup) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;span class=&quot;Note&quot;&gt;*Source: Maisel A. B-type natriuretic peptide levels: A potential novel &quot;white count&quot; for congestive heart failure. J Card Fail 2001;7(2):183-193.&lt;/span&gt; &lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            &lt;span class=&quot;Note&quot;&gt;BNP: brain natriuretic peptide; HF: heart failure; NT-proBNP: N-terminal proBNP.&lt;/span&gt; &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Recommended Imaging Tests to Assess Ventricular Function&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Recommended Imaging Tests to Assess Ventricular Function&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Echocardiogram &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Radionuclide scan &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 6&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Decide if interventions for risk factors or treatment for reversible etiologies are appropriate&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After conducting a detailed cardiopulmonary history, performing a careful physical examination, reviewing laboratory data, and completing or obtaining the results of an imaging study (if indicated), the next step is to determine whether interventions for risk factors or treatment for reversible etiologies are appropriate, available, and consistent with the patient's or advocate's wishes. Treatment of reversible causes of heart failure (see Table 6 in the original guideline document) and some exacerbations of chronic heart failure may require transferring the patient to an acute-care setting (refer to AMDA's practice guideline on transitions of care).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 7&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Develop an individualized care plan and define treatment goals&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 8&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treat the chronic underlying cardiac condition&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Treat exacerbating conditions such as anemia, diabetes, cardiac arrhythmia, fever, hyperthyroidism, infection, ischemic heart disease, and uncontrolled hypertension. Also address the consequences of the patient's failing heart. Specific pharmacotherapy should be based on the presence or absence of fluid volume overload and the nature of the ventricular dysfunction.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Nonpharmacologic interventions that may be considered in patients with heart failure include cardiopulmonary rehabilitation, increasing physical activity, decreasing smoking and alcohol consumption, and psychosocial and spiritual support. Because patients with heart failure who develop bacterial or viral respiratory infections may decompensate, all patients with heart failure should be offered pneumococcal vaccine and annual influenza vaccinations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Salt and fluid restriction may be helpful in patients who have heart failure with evidence of volume overload.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 9&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treat fluid volume overload if present&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with fluid volume overload may have dyspnea, evidence of pulmonary congestion on chest x-ray, lung crackles, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema. Start the patient with fluid volume overload on a loop diuretic immediately.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 10&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treat heart failure with reduced left ventricular ejection fraction (LVEF)&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An angiotensin-converting enzyme (ACE) inhibitor is the first-line treatment for patients with heart failure with reduced LVEF.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Medications for Treating Heart Failure with Reduced LVEF&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Medications for Treating Heart Failure with Reduced LVEF&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;ACE inhibitors (ARBs if patient cannot tolerate ACE inhibitors) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Aldosterone antagonists (in selected patients) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Beta-blockers &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Digoxin &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Diuretics &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Isosorbide dinitrate/hydralazine (in selected African American patients) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;span class=&quot;Note&quot;&gt;ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; LVEF: left ventricular ejection fraction&lt;/span&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;The patient with heart failure with reduced LVEF who has fluid volume overload should receive a loop diuretic. After fluid volume overload has been corrected, or if the patient does not have fluid volume overload, start an ACE inhibitor and titrate to the target dose as tolerated. Add a beta-blocker to ACE inhibitor therapy. Both of these drug classes have been shown to decrease morbidity and mortality in patients with heart failure. Isosorbide dinitrate and hydralazine may be added in African American patients whose heart failure remains uncontrolled on standard therapy. Digoxin may be added in selected patients to improve symptoms and enhance quality of life. Spironolactone may be introduced cautiously in selected patients with stable NYHA Class III to IV heart failure who need and want all interventions that have been demonstrated to decrease mortality.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 11&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treat heart failure with preserved LVEF&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A normal ejection fraction (greater than 40%) in the presence of pulmonary congestion and other heart failure symptoms suggests heart failure with preserved LVEF.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Medications for Treating Heart Failure with Reduced LVEF&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Table: Medication Options for Treating Heart Failure with Preserved LVEF&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;ACE inhibitors &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Beta-blockers &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Calcium-channel blockers &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Diuretics &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Nitrates &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td&gt;&lt;span class=&quot;Note&quot;&gt;ACE: angiotensin-converting enzyme inhibitor; LVEF: left ventricular ejection fraction&lt;/span&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 12&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Initiate other appropriate interventions as indicated&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Other interventions by the interdisciplinary team may be helpful.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dietary counseling is critical to assessing the need for or extent of dietary salt restriction. A rehabilitation consultation may be indicated to develop an individualized restorative exercise program.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 13&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Determine when the patient has end-stage heart failure&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients at or near the end of life, it may be appropriate to switch to a mode of care in which maintaining quality of life is the primary goal. In such cases, each intervention for heart failure must be assessed for both the palliation it provides and the intrusiveness and potential discomfort it entails.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Before the patient with heart failure develops advanced disease, he or she should be counseled about end-of-life planning and encouraged to draw up advance health care directives, if this has not already been done.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When the patient, family or advocate, and care team decide that end-of-life care is most appropriate, symptom relief and psychosocial and spiritual considerations become paramount. Management of end-of-life symptoms such as apprehension, dry mouth, dyspnea, fatigue, nausea, pain, and restlessness should be the main focus of the patient's care plan. Consultations with hospice or palliative care experts may be considered. Diuretics may be indicated as a palliative measure to address symptoms associated with fluid volume overload.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Monitoring&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 14&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the patient's condition and response to treatment&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Components of Monitoring for Heart Failure Patients&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td style=&quot;text-align: left; vertical-align: top;&quot;&gt;&lt;strong&gt;Table: Components of Monitoring for Heart Failure Patients&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Electrolytes, renal function, and magnesium, as indicated &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Functional performance &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Serum medication levels as indicated (e.g., digoxin) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Serum natriuretic peptide (BNP, NT-ProBNP) levels in select patients &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Signs and symptoms &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Vital signs &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Weight &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;span class=&quot;Note&quot;&gt;BNP: brain natriuretic peptide; NT-proBNP: N-terminal proBNP.&lt;/span&gt;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Step 15&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Monitor the facility's management of heart failure&lt;/span&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Systematic monitoring is needed to determine the extent to which the LTC facility is successfully managing patients with heart failure. The Appendix of the original guideline document suggests process and outcome indicators for measuring facility performance in the recognition, assessment, treatment, and monitoring of heart failure. Facilities may wish to select the indicators most relevant to their population and staff for inclusion in their quality improvement process. The medical director should be actively involved in this process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm is provided the original guideline document for the recognition, assessment, treatment, and monitoring of heart failure in the long-term care setting.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence supporting the recommendations is not specifically stated.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline was developed by an interdisciplinary work group using a process that combined evidence- and consensus-based approaches. Because scientific research in the long-term care population is limited, many recommendations are based on the expert opinion of practitioners in the field.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Improved recognition, assessment, treatment, and monitoring of heart failure in the long-term care (LTC) facility &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Improved staff education and awareness of heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appropriate use of medications to treat heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Greater individualization of care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enhanced quality of life for patients with heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Facilitation of patient-centered care goals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reductions in potentially avoidable hospitalizations for heart failure &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of angiotensin-converting enzyme (ACE) inhibitors include hypotension, hyperkalemia, hyponatremia, renal failure, angioedema and cough. ACE inhibitors also interact with drugs such as lithium and potassium-sparing agents and increase the potential for toxicity and electrolyte disturbance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of beta-blockers include depression, symptomatic bradycardia or heart block, symptomatic hypotension, profound fatigue, increased shortness of breath, and exacerbation of heart failure. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperkalemia may occur in patients treated with aldosterone antagonists. Spironolactone also blocks androgen receptors, potentially causing gynecomastia. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The most common adverse effects seen with isosorbide dinitrate/hydralazine are gastrointestinal complaints and headache (caused by the vasodilatory effects of the drug combination). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Contraindications to Use of Angiotensin-converting Enzyme (ACE) Inhibitors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Absolute Contraindications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Angioedema &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypersensitivity to ACE inhibitors &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Relative Contraindications&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cough &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Renal artery stenosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Serum potassium greater than 5.5 mEq/L &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Systolic blood pressure less than 90 mm Hg or &amp;lt;100 mm Hg if patient is symptomatic &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Contraindications to Use of Beta-blockers&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients who have acutely decompensated heart failure or any of the following conditions should not take beta-blockers:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Bradycardia or advanced heart block without a pacemaker &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypotension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Need for intravenous therapy for heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reactive airways disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Requirement for hospitalization for heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Severe peripheral arterial disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sick sinus syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Significant fluid retention requiring intensive diuretic therapy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This clinical practice guideline is provided for discussion and educational purposes only and should not be used or in any way relied upon without consultation with and supervision of a qualified physician based on the case history and medical condition of a particular patient. The American Medical Directors Association (AMDA), its heirs, executors, administrators, successors, and assigns hereby disclaim any and all liability for damages of whatever kind resulting from the use, negligent or otherwise, of this clinical practice guideline. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The utilization of AMDA's Clinical Practice Guideline does not preclude compliance with State and Federal regulation as well as facility policies and procedures. They are not substitutes for the experience and judgment of clinicians and caregivers. The Clinical Practice Guidelines are not to be considered as standards of care but are developed to enhance the clinicians' ability to practice. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The corporate supporters of this guideline provided funding without condition of product use, formulary status or purchasing commitment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Long-term care facilities care for a variety of individuals, including younger patients with chronic diseases and disabilities, short-stay patients needing postacute care, and very old and frail individuals suffering from multiple comorbidities. When a workup or treatment is suggested, it is crucial to consider if such a step is appropriate for a specific individual. A workup may not be indicated if the patient has a terminal or end-stage condition, if it would not change the management course, if the burden of the workup is greater than the potential benefit, or if the patient or his or her proxy would refuse treatment. It is important to carefully document in the patient's medical record the reasons for decisions not to treat or perform a workup or for choosing one treatment approach over another. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The implementation of this clinical practice guideline (CPG) is outlined in four phases. Each phase presents a series of steps, which should be carried out in the process of implementing the practices presented in this guideline. Each phase is summarized below.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Recognition&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Define the area of improvement and determine if there is a CPG available for the defined area. Then evaluate the pertinence and feasibility of implementing the CPG. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Assessment&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Define the functions necessary for implementation and then educate and train staff. Assess and document performance and outcome indicators and then develop a system to measure outcomes. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Implementation&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Identify and document how each step of the CPG will be carried out and develop an implementation timetable. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Identify individual responsible for each step of the CPG. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Identify support systems that impact the direct care. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Educate and train appropriate individuals in specific CPG implementation and then implement the CPG. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Monitoring&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Evaluate performance based on relevant indicators and identify areas for improvement. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Evaluate the predefined performance measures and obtain and provide feedback. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Clinical Algorithm" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="End of Life Care" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Medical Directors Association (AMDA). Heart  failure in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2010. 24 p.  [71 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="1996 (revised 2010)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Medical Directors Association - Professional Association" /></Field><Field FieldID="123" OrdBy="1230" ID="448" Name="Guideline Developer Comment" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Organizational participants included:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;American Association of Homes and Services for the Aging &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American College of Health Care Administrators &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Geriatrics Society &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Health Care Association &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;American Society of Consultant Pharmacists &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gerontological Advanced Practice Nurses Association &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Association of Directors of Nursing Administration in Long-Term Care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National Association of Health Care Assistants &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Medical Directors Association&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Clinical Practice Guideline Steering Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Charles Cefalu, MD, MS, &lt;em&gt;Clinical Practice Committee Chair&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Hosam Kamel, MD, CMD, &lt;em&gt;CPG Chair&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Steering Committee Members&lt;/em&gt;: Charles Cefalu, MD, MS (&lt;em&gt;Chair&lt;/em&gt;); Judith L. Beizer, PharmD, CGP, FASCP; Sandra Fitzler, RN; Marianna Grachek, MSN, CNHA, CALA; Joseph Gruber, RPh, FASCP, CGP; Regina Kaurich, RN, MBA; Susan M. Levy, MD, CMD; Evvie F. Munley; Jonathan Musher, MD, CMD; Barbara Resnick, PhD, CRNP&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Contributors to 2010 Update&lt;/em&gt;: Hosam Kamel, MD, CMD (&lt;em&gt;Chair&lt;/em&gt;); *Charles Cefalu, MD, MS (&lt;em&gt;Project Chair&lt;/em&gt;); Wilbert S. Aronow, MD, FACC, FAHA, AGSF; Harold Bob, MD, CMD; Rebecca Boxer, MD; Terry Oshea, PharmD, CGP; Thomas Price, MD, CMD; Krystal Thomas, GNP, BC; William Smucker, MD, CMD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Contributors to the 2003 Update&lt;/em&gt;: *Larry W. Lawhorne, MD, CMD (&lt;em&gt;CPG Project Chair&lt;/em&gt;); *Steven Levenson, MD, CMD (&lt;em&gt;Chair&lt;/em&gt;); *Donna Brickley, RN; *Lisa Cantrell, RN, C; *Charles Cefalu, MD, MS; Woody Eisenberg, MD, FACP; Jesus Evangelista, MD, CMD; *Joseph Gruber, RPh, FASCP, CGP; *Susan M. Levy, MD, CMD; *Betty MacLaughlin-Fransden, RN, NHA; Harlan Martin, RPh, CCP, FASCP; *Geri Mendelson, RN, CNAA, MEd, NHA; *Evvie F. Munley; *Jonathan Musher, MD, CMD; *Judith A. Passerini, CNHA, CAS, Fellow; *Mary Pat Rapp, MSN, RN; *Barbara Resnick, PhD, CRNP; *William Simonson, PharmD, FASCP, CGP; John Voytas, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Original Panel Members&lt;/em&gt;: *Jerry Johnson, MD (&lt;em&gt;Chair&lt;/em&gt;); Manju Beier, PharmD; Ellie Cohn, RN, MS, CRRN; Janet E. George, RN (&lt;em&gt;Facilitator&lt;/em&gt;); Patrick W. Irvine, MD, CMD; Steven Levenson, MD, CMD; Tim Mislan, BSN, MS; Joyce Smith, RN; Ann Wells, RN; Danielle Dodman, MS, CCC-SLP&lt;/p&gt;&#xD;&#xA;&lt;p&gt;*Steering Committee Member&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Technical Writer&lt;/em&gt;: Jennifer Holmes&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;AMDA Staff&lt;/em&gt;: Jacqueline Vance, RN, C. CDONA/LTC, CPG Project Manager, Director of Clinical Affairs&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All contributors must submit an Accreditation Council for Continuing Medical Education (ACCME) approved disclosure form prior to being accepted as a volunteer member of the guideline workgroup. This disclosure form is reviewed by the chair of the American Medical Directors Association (AMDA) Clinical Practice Committee. If any conflicts are perceived, that person is not accepted to be part of the workgroup.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: American Medical Directors Association (AMDA). Heart failure. Columbia (MD): American Medical Directors Association (AMDA); 2002. 18 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Not available at this time.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Medical Directors Association, 10480 Little Patuxent Pkwy, Suite 760, Columbia, MD 21044. Telephone: (800) 876-2632 or (410) 740-9743; Fax (410) 740-4572. Web site: &lt;a href=&quot;http://www.amda.com&quot; title=&quot;AMDA Web site&quot;&gt;www.amda.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The appendix of the original guideline document offers suggestions for&#xA;general process indicators as well as clinical process and outcome&#xA;indicators specific to measuring facility performance in heart failure&#xA;management.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on July 12, 1999. The information was verified by the American Medical Directors Association as of August 8, 1999. This summary was updated on December 3, 2002. The information was verified by the guideline developer on December 10, 2002. This NGC summary was updated by ECRI Institute on October 4, 2011. The updated information was verified by the guideline developer on November 29, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is copyrighted by the American Medical Directors Association (AMDA) and the American Health Care Association. Written permission from AMDA must be obtained to duplicate or disseminate information from the original guideline. For more information, contact AMDA at (410) 740-9743.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
